In non-segmental vitiligo, ruxolitinib improves repigmentation compared to vehicle control
1. A higher percentage of patients using ruxolitinib achieved at least a 75% reduction in Facial Vitiligo Area Scoring Index (F-VASI) at 24 weeks compared to vehicle controls. 2. Significantly…